| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Abietic acid targets multiple pathways. It is a potent inhibitor of testosterone 5α-reductase and lipoxygenase (IC50 = 29.5 ± 1.29 µM). It acts as a PPARα/γ dual activator, an IKKβ inhibitor, and suppresses NF-κB and the MAPK/AP-1 pathway.
|
|---|---|
| ln Vitro |
In vitro, abietic acid inhibits soybean 5-lipoxygenase with an IC50 of 29.5 ± 1.29 µM. It acts as a PPARα/γ dual activator to inhibit UVB-induced MMP-1 expression and age-related inflammation. It has antibacterial and anti-inflammatory effects.
|
| ln Vivo |
In vivo, abietic acid has anti-inflammatory effects by inhibiting the expression of genes involved in inflammation such as TNF-α and COX-2 in LPS-induced macrophages. It exhibits a positive effect against liver injury by attenuating inflammation and ferroptosis and shows accelerated wound closure in a mouse model of cutaneous wounds.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for abietic acid typically involve evaluating its inhibitory activity against 5-lipoxygenase or 5α-reductase using enzymatic activity assays. IC50 values are determined by measuring product formation.
|
| Cell Assay |
For in vitro cell-based assays, abietic acid is dissolved in DMSO and applied to cultured macrophages or cancer cells at concentrations ranging from 1-100 µM. Effects on cytokine production, cell proliferation, or gene expression are assessed after 24-72 hours of treatment.
|
| Animal Protocol |
In vivo animal studies commonly use mouse models of inflammation or wound healing. Abietic acid is administered orally or topically at doses ranging from 1-100 mg/kg. Efficacy is evaluated by measuring inflammatory markers, wound closure, or tissue histopathology.
|
| ADME/Pharmacokinetics |
Abietic acid has a molecular weight of approximately 300 g/mol. It is a diterpene compound found in rosin. It is soluble in organic solvents.
|
| Toxicity/Toxicokinetics |
Abietic acid has a favorable safety profile with no significant toxicity reported at research doses. It is a natural compound with a long history of use.
|
| References | |
| Additional Infomation |
Yellowish resinous powder. (NTP, 1992)
Abietic acid is a rosinane diterpenoid compound formed by the substitution of a rosin-7,13-diene with a carboxyl group at the 18th position. It is a plant metabolite. It is a rosinane diterpenoid compound and also a monocarboxylic acid. It is the conjugate acid of rosin esters. Abietic acid has been reported to be found in Pinus densiflora, Ceroplastes pseudoceriferus, and other organisms with relevant data. See also: Rosin (note moved to); Levamisole resin esters (note moved to). Abietic acid is used in industrial applications such as adhesives and varnishes. It has antimicrobial and anti-inflammatory effects and is studied in pharmacology for potential applications in treating inflammation and bacterial infections. It is also used for regulating lipid metabolism and atherosclerosis. |
| Molecular Formula |
C20H30O2
|
|---|---|
| Molecular Weight |
302.46
|
| Exact Mass |
302.224
|
| CAS # |
514-10-3
|
| Related CAS # |
10248-55-2 (unspecified copper salt);13463-98-4 (calcium salt);14351-66-7 (hydrochloride salt);23250-44-4 (potassium salt);66104-40-3 (strontium salt);66104-41-4 (barium salt);67816-10-8 (Pd(+2) salt);6798-76-1 (zinc salt)
|
| PubChem CID |
10569
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
439.5±44.0 °C at 760 mmHg
|
| Melting Point |
139-142 °C(lit.)
|
| Flash Point |
208.1±23.1 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.542
|
| LogP |
6.51
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
542
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC(C)C1=CC2=CC[C@@H]3[C@@]([C@H]2CC1)(CCC[C@@]3(C)C(=O)O)C
|
| InChi Key |
RSWGJHLUYNHPMX-ONCXSQPRSA-N
|
| InChi Code |
InChI=1S/C20H30O2/c1-13(2)14-6-8-16-15(12-14)7-9-17-19(16,3)10-5-11-20(17,4)18(21)22/h7,12-13,16-17H,5-6,8-11H2,1-4H3,(H,21,22)/t16-,17+,19+,20+/m0/s1
|
| Chemical Name |
(1R,4aR,4bR,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid
|
| Synonyms |
NSC-25149; NSC 25149; Abietic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~330.63 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.27 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3062 mL | 16.5311 mL | 33.0622 mL | |
| 5 mM | 0.6612 mL | 3.3062 mL | 6.6124 mL | |
| 10 mM | 0.3306 mL | 1.6531 mL | 3.3062 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
